Source comparison
TB-500 Studied Post-Surgery Recovery: Research Comparison
Rat laparotomy Abdominal adhesion prevention 5 mg/kg intraperitoneal, single dose post-op Adhesion score at 14 days 63% reduction in adhesion formation J Surg Res 2019 Most significant adhesion reduction data to date. Mechanism likely involves fibrinolytic pat
This comparison does not assign a generated winner or score.
- Rat laparotomy
- Abdominal adhesion prevention
- 5 mg/kg intraperitoneal, single dose post-op
- Adhesion score at 14 days
- 63% reduction in adhesion formation
- J Surg Res 2019
- Most significant adhesion reduction data to date. Mechanism likely involves fibrinolytic pathway modulation
- Equine tendon repair
- Superficial digital flexor tendon lesion
- 20 mg subcutaneous, twice weekly × 4 weeks
- Tensile strength and fiber alignment on ultrasound
- 27% greater tensile strength, 19% improved alignment
- Equine Vet J 2016
- Gold standard for tendon healing models. Results directly applicable to human soft tissue repair contexts
- Canine soft tissue incision
- Post-operative wound closure
- Topical gel (0.1% TB-500), applied daily × 10 days
- Time to complete wound closure
- 40% faster closure, reduced scar width
- Vet Surg 2021
- Topical application bypasses systemic exposure concerns. Promising for translation to human incision care
- Rat myocardial infarction
- Post-infarct tissue repair
- 6 mg/kg intraperitoneal, 3× weekly × 4 weeks
- Capillary density in infarcted tissue
- 31% greater capillary density
- Cardiovasc Res 2020
- Demonstrates TB-500's angiogenic effect extends beyond wound healing to ischemic tissue repair